• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ProSomnus Inc. (Amendment)

    2/14/23 4:15:53 PM ET
    $OSA
    Medical Specialities
    Health Care
    Get the next $OSA alert in real time by email
    SC 13G/A 1 Prosomnus_Amend.txt Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* (Name of Issuer) ProSomnus, Inc. f/k/a Lakeshore Acquisition I Corp (Title of Class of Securities) Common Stock, par value $0.0001 per share (CUSIP Number) 50535E108 (Date of Event Which Requires Filing of this Statement) 12/31/2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) CUSIP No. 50535E108 (1) Names of reporting persons Polar Asset Management Partners Inc. (2) Check the appropriate box if a member of a group (see instructions) (a) (b) (3) SEC use only (4) Citizenship or place of organization Ontario, Canada Number of shares beneficially owned by each reporting person with: (5) Sole voting power 814,404(including 251,858 Shares issuable upon the exercise of warrants) (6) Shared voting power (7) Sole dispositive power 814,404 (including 251,858 Shares issuable upon the exercise of warrants) (8) Shared dispositive power (9) Aggregate amount beneficially owned by each reporting person 814,404 (including 251,858 Shares issuable upon the exercise of warrants) (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 5.00% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: ProSomnus, Inc. f/k/a Lakeshore Acquisition I Corp Item 1(b) Address of issuer's principal executive offices: 5675 Gibraltar Avenue Pleasanton, California, 94588 2(a) Name of person filing: This statement is filed by Polar Asset Management Partners Inc., a company incorporated under the laws of Ontario, Canada, which serves as the investment advisor to Polar Multi-Strategy Master Fund, a Cayman Islands exempted company ("PMSMF") with respect to the Shares (as defined below) directly held by PMSMF. 2(b) Address or principal business office or, if none, residence: 16 York Street, Suite 2900, Toronto, ON, Canada M5J 0E6. 2(c) Citizenship: Canada 2(d) Title of class of securities: Common Stock, par value $0.0001 per share 2(e) CUSIP Number: 50535E108 Item 3. [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o); [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c); [ ] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c); [ ] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); [ ] An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); [ ] An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); [ ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3); [x] A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J); [ ] Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: The Reporting Person is an investment fund manager, portfolio manager, exempt market dealer and commodity trading manager registered with the Ontario Securities Commission. Item 4. Ownership As of December 31, 2022 1. Polar Asset Management Partners Inc. (a) Amount beneficially owned: 814,404 (including 251,858 Shares issuable upon the exercise of warrants) (b) Percent of class: 5.00% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 814,404 (including 251,858 Shares issuable upon the exercise of warrants) (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 814,404 (including 251,858 Shares issuable upon the exercise of warrants) (iv) Shared power to dispose or to direct the disposition of: 0 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following []. Instruction. Dissolution of a group requires a response to this item. Not applicable Item 6. Ownership of More than 5 Percent on Behalf of Another Person. Not applicable Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reporting on by the Parent Holding Company or Control Person. Not applicable Item 8. Identification and Classification of Members of the Group Not applicable Item 9. Notice of Dissolution of Group. Not applicable Item 10. Certifications By signing below I certify that, to the best of his/her knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 14, 2023 POLAR ASSET MANAGEMENT PARTNERS INC. By: /s/ Andrew Ma Name: Andrew Ma Title: Chief Compliance Officer
    Get the next $OSA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OSA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Kim Sung was granted 315,742 shares, increasing direct ownership by 157% to 516,808 units (SEC Form 4)

    4 - ProSomnus, Inc. (0001934064) (Issuer)

    2/16/24 6:20:29 PM ET
    $OSA
    Medical Specialities
    Health Care

    Dow Brian B was granted 315,742 shares, increasing direct ownership by 337% to 409,492 units (SEC Form 4)

    4 - ProSomnus, Inc. (0001934064) (Issuer)

    2/16/24 6:16:43 PM ET
    $OSA
    Medical Specialities
    Health Care

    Liptak Len was granted 1,322,756 shares, increasing direct ownership by 208% to 1,957,216 units (SEC Form 4)

    4 - ProSomnus, Inc. (0001934064) (Issuer)

    2/16/24 6:14:33 PM ET
    $OSA
    Medical Specialities
    Health Care

    $OSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results

    PLEASANTON, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA), the leading non-CPAP therapy™ for the treatment of Obstructive Sleep Apnea (OSA), today announced financial results for the fourth quarter and year ended December 31, 2023. Recent Business Highlights Generated record revenues of $7.8 million for the fourth quarter and $27.7 million for the fiscal year 2023, a 35% increase compared to $5.8 million for the fourth quarter 2022 and 43% increase compared to $19.4 million for fiscal year 2022. The quarter marked the eighth (8th) sequential quarter of record revenues.Continued focus on implementing reductions in operating expenses. Operating expenses, excludin

    3/26/24 4:05:00 PM ET
    $OSA
    Medical Specialities
    Health Care

    ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call

    PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced today it has postponed the release of its 2023 fourth quarter and full year financial results and the related investor conference call. The rescheduled call will be held after market close on Tuesday, March 26, 2024 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Registration and dial-in information can be found on the investor relations website. Additionally, the Company will not be attending the Roth Conference. About ProSomnusProSomnus (NASDAQ: OSA) is the leading non-CPAP therapy for the treatment of Obstructiv

    3/15/24 8:01:20 PM ET
    $OSA
    Medical Specialities
    Health Care

    ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea

    PLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced results of its pilot study for the Company's Next Generation Remote Patient Monitoring (RPM) device for Obstructive Sleep Apnea (OSA). Data from the pilot study demonstrated that an oximeter embedded in a precision medical device can accurately, safely, and continuously monitor SpO2. "This pilot study validation represents a step toward bringing sleep medicine into the P4 medicine era. The ProSomnus® RPMO2 OSA Device enables sleep medicine to be more personalized, predictive, preventative, and participatory," commented L

    2/22/24 8:30:00 AM ET
    $OSA
    Medical Specialities
    Health Care

    $OSA
    SEC Filings

    View All

    ProSomnus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ProSomnus, Inc. (0001934064) (Filer)

    5/8/24 9:25:27 AM ET
    $OSA
    Medical Specialities
    Health Care

    ProSomnus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - ProSomnus, Inc. (0001934064) (Filer)

    4/30/24 4:51:50 PM ET
    $OSA
    Medical Specialities
    Health Care

    SEC Form 10-K/A filed by ProSomnus Inc. (Amendment)

    10-K/A - ProSomnus, Inc. (0001934064) (Filer)

    4/29/24 5:29:15 PM ET
    $OSA
    Medical Specialities
    Health Care

    $OSA
    Financials

    Live finance-specific insights

    View All

    ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results

    PLEASANTON, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA), the leading non-CPAP therapy™ for the treatment of Obstructive Sleep Apnea (OSA), today announced financial results for the fourth quarter and year ended December 31, 2023. Recent Business Highlights Generated record revenues of $7.8 million for the fourth quarter and $27.7 million for the fiscal year 2023, a 35% increase compared to $5.8 million for the fourth quarter 2022 and 43% increase compared to $19.4 million for fiscal year 2022. The quarter marked the eighth (8th) sequential quarter of record revenues.Continued focus on implementing reductions in operating expenses. Operating expenses, excludin

    3/26/24 4:05:00 PM ET
    $OSA
    Medical Specialities
    Health Care

    ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call

    PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced today it has postponed the release of its 2023 fourth quarter and full year financial results and the related investor conference call. The rescheduled call will be held after market close on Tuesday, March 26, 2024 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Registration and dial-in information can be found on the investor relations website. Additionally, the Company will not be attending the Roth Conference. About ProSomnusProSomnus (NASDAQ: OSA) is the leading non-CPAP therapy for the treatment of Obstructiv

    3/15/24 8:01:20 PM ET
    $OSA
    Medical Specialities
    Health Care

    ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024

    PLEASANTON, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA), the leading non-CPAP therapy for the treatment of Obstructive Sleep Apnea (OSA), announced today that it will report its fourth quarter and fiscal year 2023 financial results and provide a business update before market open on Monday, March 18, 2024 at the 36th Annual ROTH Conference and via a live webcast. ProSomnus Chief Executive Officer, Len Liptak, and Chief Financial Officer, Brian Dow, will host a conference call at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Following the call, management will participate in the 36th Annual ROTH Conference, being held March 17-19, 2024. Fourth Quarter and Fisc

    2/20/24 4:05:00 PM ET
    $OSA
    Medical Specialities
    Health Care

    $OSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by ProSomnus Inc.

    SC 13G - ProSomnus, Inc. (0001934064) (Subject)

    2/14/24 11:10:52 AM ET
    $OSA
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by ProSomnus Inc. (Amendment)

    SC 13G/A - ProSomnus, Inc. (0001934064) (Subject)

    2/12/24 11:46:53 AM ET
    $OSA
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by ProSomnus Inc. (Amendment)

    SC 13D/A - ProSomnus, Inc. (0001934064) (Subject)

    12/8/23 4:15:31 PM ET
    $OSA
    Medical Specialities
    Health Care